Intraocular Retinoblastoma Clinical Trial
Official title:
Carcinogen Metabolism, DNA Repair, Parental Exposures and Retinoblastoma
This laboratory study is looking at genetic mutations and environmental exposure in young patients with retinoblastoma and in their parents and young healthy unrelated volunteers. Gathering information about gene mutations and environmental exposure may help doctors learn more about the causes of retinoblastoma in young patients.
OBJECTIVES:
I. To investigate the role of genotypes for carcinogen metabolizing enzymes (CME) and DNA
repair proteins(DRPs) of the father of children diagnosed with retinoblastoma (RB) and his
environmental exposures prior to the child?s conception in the etiology of sporadic bilateral
retinoblastoma.
II. To test if the prevalence of preconception environmental exposures and polymorphisms with
known or predicted functional consequences in genes for CMEs and DRPs is different in fathers
of children with sporadic bilateral RB compared with fathers of the control group.
III. To test if the prevalence of the father?s preconception environmental exposures and his
polymorphisms in CMEs and DRPs differs between subsets of cases defined by the type of
mutation at the RB1 gene locus.
IV. To investigate the role of genotypes for CMEs and DRPs of the mother and child and
environmental exposures after the child?s conception in the etiology of sporadic unilateral
RB.
V. To test if the prevalence of environmental exposures during the pregnancy and
polymorphisms with known or predicted functional consequences in CMEs is different in the
mothers of children with sporadic unilateral RB compared with mothers of the control group.
VI. To test if the prevalence of polymorphisms in genes for CMEs and DRPs with known or
predicted functional consequences is different in the children with sporadic unilateral RB
compared with controls.
VII. To test if the prevalence of gestational exposures and polymorphisms in genes for CMEs
of the mother and the polymorphisms in genes for CME and DRPs in the children differs between
subsets of cases defined by the type of mutation at the RB1 gene locus.
OUTLINE: This is a multicenter study.
Participants undergo a structured telephone interview questionnaire. The parental
questionnaires collect basic demographic data (including age, race, education, and income),
occupational history, medical radiation exposure, diet and supplement use (for the year
before pregnancy for father, during pregnancy for mother), tobacco use, and alcohol use. The
mothers are also asked about residential pesticides and prior assisted reproductive
technology.
Controls (parents) provide saliva samples. If a patient is also enrolled on COG-ARET0332,
then the patient blood and tumor samples should be submitted. Parents of patients on this
protocol should also submit a blood sample. Blood samples from the affected child, and blood
and/or sputum samples from the parents may be submitted. Tumor specimens should be submitted
if available.
For some patients, a RB1 mutation detection assay on DNA derived from peripheral blood is
performed. If the mutation is found, the parents? DNA is also screened. Blood samples undergo
DNA-based sequencing analysis, single nucleotide polymorphism genotyping, quantitative
Southern blot analysis, isolation of RNA and reverse transcriptase-polymerase chain reaction
analysis, and loss of heterozygosity analysis.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03866460 -
Determining Whether Intra-Arterial Carboplatin Causes Hearing Loss in Children
|
||
Recruiting |
NCT03932786 -
Studying Health Outcomes After Treatment in Patients With Retinoblastoma
|
||
Completed |
NCT00079417 -
Neoadjuvant Carboplatin and Vincristine and Standard Local Ophthalmic Therapy in Treating Patients With Intraocular Retinoblastoma
|
Phase 3 | |
Completed |
NCT00335738 -
Vincristine, Carboplatin, and Etoposide or Observation Only in Treating Patients Who Have Undergone Surgery for Newly Diagnosed Retinoblastoma
|
Phase 3 | |
Active, not recruiting |
NCT00889018 -
Trial Comparing Two Carboplatin Doses in Groups C and D Intraocular Retinoblastoma
|
N/A | |
Completed |
NCT00072384 -
Systemic Chemotherapy and Subtenon Carboplatin, and Local Ophthalmic Therapy in Children With Intraocular Retinoblastoma
|
Phase 3 |